Skip to main content
Events
GroupKALSHI

FDA decision: Venglustat by Sanofi (in 2026)

FDA decision: Venglustat by Sanofi (in 2026)
Vol

$0.00

|
Events

1

|
Markets

1

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

82%
Top Probability
$0.00
Volume
1
Markets
1
Platforms

About This Event

FDA decision on Venglustat in 2026 If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which build

AI-generated analysis based on market data. Not financial advice.

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

Market Insights

Average Yes Price
82¢
Kalshi
Arbitrage Opps
0
Cross-Platform
0

Trade This Market